Latest news
China accepts NDA for Alebund's phosphate binder AP301 after Phase III success - AllSciAllSci · Fri, 07 Aug 2026 16:31:47 GMTAlebund's AP301 NDA Accepted for Review by China's NMPA - The Manila TimesThe Manila Times · Fri, 07 Aug 2026 11:01:01 GMTIn a first, Otsuka’s Voyxact stabilizes IgAN patients’ kidney function decline to normal levels - Fierce PharmaFierce Pharma · Mon, 03 Aug 2026 21:00:00 GMT